Stock Events

Stock Events

CorMedix 

€5.8
108
+€0.1+1.75% Thursday 06:05

Statistics

Day High
5.6
Day Low
5.6
52W High
14.6
52W Low
5.2
Volume
-
Avg. Volume
-
Mkt Cap
456.98M
P/E Ratio
15.07
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.25
0.25
0.76
1.26
Expected EPS
0.468571
Actual EPS
N/A

Financials

-40.17%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
83.19MRevenue
-33.42MNet Income

Analyst Ratings

$10.62Average Price Target
The highest estimate is 12.14.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 19KA.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical company that competes with CorMedix in the development of drugs for infectious diseases, including those targeted by CorMedix's lead product, DefenCath.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is involved in the discovery, development, manufacturing, and marketing of pharmaceuticals that directly compete with CorMedix's portfolio, especially in the antimicrobial space.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical segment, competes in the development and marketing of products that could be used in similar indications as CorMedix's, including infection prevention.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories offers a wide range of healthcare products that compete with CorMedix, particularly in the area of medical devices and diagnostics for infectious diseases.
AMGEN
AMGN
Mkt Cap160.66B
Amgen competes with CorMedix in the biopharmaceutical field, focusing on innovative treatments that could overlap with CorMedix's market, especially in the area of infection control.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in areas that compete with CorMedix, particularly in the treatment of infectious diseases.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb is involved in the discovery and development of drugs in areas that could compete with CorMedix, including therapies for preventing and treating infections.
Novartis
NVS
Mkt Cap237.61B
Novartis AG competes with CorMedix in the global healthcare market, particularly in the development and marketing of products for the treatment of various diseases, including those targeted by CorMedix.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is a global, science-led biopharmaceutical business that competes with CorMedix in the development and commercialization of medicines for various diseases, including infections.
Sanofi
SNY
Mkt Cap124.45B
Sanofi is a global healthcare leader that competes with CorMedix in the areas of pharmaceuticals, including the development of treatments for infections similar to those targeted by CorMedix.

About

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Show more...
CEO
Mr. Joseph Todisco MBA
Employees
64
Country
US
ISIN
US21900C3088
WKN
000A2PF3G

Listings

XNAS
US
CRMD
F
DE
19KA.F
BOATS
BOATS
CRMD.BOATS

0 Comments

Share your thoughts

FAQ

What is CorMedix stock price today?▼
The current price of 19KA.F is €5.8 EUR — it has increased by +1.75% in the past 24 hours. Watch CorMedix stock price performance more closely on the chart.
What is CorMedix stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange CorMedix stocks are traded under the ticker 19KA.F.
Is CorMedix stock price growing?▼
19KA.F stock has risen by +2.65% compared to the previous week, the month change is a -1.69% fall, over the last year CorMedix has showed a +8.41% increase.
What is CorMedix market cap?▼
Today CorMedix has the market capitalization of 456.98M
When is the next CorMedix earnings date?▼
CorMedix is going to release the next earnings report on May 07, 2026.
What were CorMedix earnings last quarter?▼
19KA.F earnings for the last quarter are 0.14 EUR per share, whereas the estimation was 0.7 EUR resulting in a -80.4% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is CorMedix revenue for the last year?▼
CorMedix revenue for the last year amounts to 83.19M EUR.
What is CorMedix net income for the last year?▼
19KA.F net income for the last year is -33.42M EUR.
How many employees does CorMedix have?▼
As of April 03, 2026, the company has 64 employees.
In which sector is CorMedix located?▼
CorMedix operates in the Health Care sector.
When did CorMedix complete a stock split?▼
The last stock split for CorMedix was on March 26, 2019 with a ratio of 1:5.
Where is CorMedix headquartered?▼
CorMedix is headquartered in Berkeley Heights, US.